DESCRIPTION

AGS has developed preliminary advice to help clinicians in assisting their patients and surrogates to be fully informed about the risks and benefits of lecanemab based on the available data. Annotated inclusion and exclusion criteria tables are additionally available as a downloadable checklist for use in clinical practice.

Writing Workgroup

Esther Oh, MD, PhD

Heather Whitson, MD, AGSF

Nancy Lundebjerg, MPA

Aimee Cegelka, MA

Mike Harper, MD

Mark Supiano, MD, AGSF

Reviewers

Soo Borson, MD

Peter Hollman, MD, AGSF

Elvy Ickowicz, MPH

Fred Kobylarz, MD, MPH

William Lyons, MD, AGSF

Todd Semla, PharmD, MS, AGSF

Belinda Setters, MD, AGSF

Eric Widera, MD

Final approval

The AGS Executive Committee reviewed and approved this document and made recommendations on behalf of the AGS Board of Directors on November 17, 2023.